GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
Sebi comes out with composition of internal audit team for CRAs
14/05/2025
Pak conflict : Indian QSR stock with Turkey ops in crossfire amid boycott calls
14/05/2025
MSCI Smallcap Index Rejig : Tata Tech, Hexaware among 11 stocks added ; 22 shown the door
14/05/2025
LIC Mutual Fund reintroduces five flagship equity schemes ; details here
14/05/2025
Iran rejects Trump's negative portrayal of its regional role
14/05/2025
JM Financial bets on banks, capex-led growth stocks in new model portfolio
14/05/2025
